Novo i USA ca 327.50 fwiw
1 Like
snart under 50 usd over dammen, tilsvarer vel 325
1 Like
Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Company’s first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.
By
Follow
Updated July 30, 2025 10:55 am ET
Novo Nordisk’s incoming chief executive, Maziar Mike Doustdar. Photo: Novo Nordisk
Quick Summary
- Novo Nordisk’s incoming CEO Maziar Mike Doustdar faces challenges in the U.S. market, where the company struggles against competitors like Eli Lilly.
View more
In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss drug Wegovy on the popular telehealth service Hims & Hers.
Advertisement
The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other telehealth companies were selling.
But within weeks, Novo Nordisk’s partnership crumbled amid a messy war of words. Novo Nordisk accused Hims & Hers of continuing to deceptively sell large volumes of copycat versions of Wegovy. Hims & Hers blasted Novo Nordisk, saying Novo Nordisk improperly pressured it to steer patients to brand-name Wegovy.
Hims & Hers is still selling compounded Wegovy, which the U.S. Food and Drug Administration had allowed while the drug was in shortage, even though that shortage is now over.
Novo Nordisk has consistently misread the U.S. market and the threat of compounders, which make alternative versions of anti-obesity drugs. This culminated in the implosion of the high-profile deal with Hims & Hers in June—and Novo Nordisk’s warning Tuesday that its full-year sales and earnings would be lower than expected, which sent its stock price plunging. In early trading Wednesday, Novo Nordisk shares fell about 6%.
Now, some industry observers doubt whether incoming Chief Executive Maziar Mike Doustdar, the company’s first non-Danish leader but nevertheless a longtime company insider, can fix that. He has experience leading international operations, but not in the U.S., where Novo Nordisk’s biggest competitive threats lie, including rival Eli Lilly, which has a more effective drug in Zepbound.
Doustdar is a lifer at Novo Nordisk. He started at the company as an office clerk in what he thought would be a summer job in the early 1990s in Austria and then moved up through various roles including in finance, tech, operations, and parts of Novo Nordisk’s emerging markets. The 54-year-old has a degree in international business and had leadership posts in Eastern Europe, the Middle East and Southeast Asia.
Novo Nordisk faces competition from lower-cost compounded drugs, such as those sold by Hims & Hers. Photo: Gabby Jones/Bloomberg News
He makes regular visits to Novo Nordisk sites around the world. His LinkedIn page is dotted with selfies taken with Novo Nordisk staff in China, Italy, Singapore, Sweden and Saudi Arabia. He oversaw efforts to roll out Novo Nordisk’s anti-obesity drugs—starting with Saxenda a decade ago and later Wegovy—in places such as Mexico and South America.
Some analysts were expecting someone from outside the company to take over, given its challenges.
“Is that the right person to be put in a role when the U.S. is such a driver of the business?” said BMO Capital Markets analyst Evan David Seigerman.
About one million people still rely on compounded versions of semaglutide, the main ingredient in Wegovy and Novo Nordisk’s diabetes drug Ozempic, to shed pounds, the company said. Novo Nordisk was expecting patient use to decline this year. Novo Nordisk figured that its resolution of the shortage was supposed to prohibit mass production of knockoffs under U.S. law.
Instead, compounding pharmacies and telehealth companies have continued to sell the copies of semaglutide, using a loophole that allows them to make custom-made versions for individual patients.
The compounded versions have typically been cheaper than the branded drugs. Hims & Hers, for example, sells compounded semaglutide for as low as $199 a month. For people without insurance coverage wanting brand-name Wegovy, Novo Nordisk offers a cash price of $299 for the first month, rising to $499 a month thereafter.
The competition from lower-cost compounded drugs was a big factor behind Novo Nordisk’s disclosure Tuesday that its sales and operating profit growth for full-year 2025 would be lower than expected.
Novo Nordisk also faces tough competition from Eli Lilly, whose anti-obesity drug Zepbound and diabetes drug Mounjaro have surpassed Wegovy and Ozempic in U.S. prescription volume. Weekly prescriptions for Mounjaro have averaged 610,776 in the third quarter, versus 581,489 for Ozempic, according to J.P. Morgan analysts, citing data from Iqvia. Zepbound has averaged 403,660 prescriptions a week, above the 250,872 for Wegovy.
At the same time, the company was expecting more from the online direct-to-consumer service it launched in March, which was intended as a way to get people to switch from compounded versions to the original brand. The company sells original Wegovy to cash-paying patients, and provides home delivery of the drug.
Novo Nordisk said Tuesday that the cash-pay business is growing, albeit more slowly than expected.
Novo Nordisk’s challenges from both a pharmaceutical giant in Lilly and the low-cost competition from compounded drugs sellers led to its leadership change. Novo Nordisk announced in May that Lars Fruergaard Jorgensen, CEO since 2017, was departing ahead of schedule.
Injection pens for Wegovy, Novo Nordisk’s weight-loss drug. Photo: Dhiraj Singh/Bloomberg News
Born in Iran, Doustdar grew up in the U.S. and is an Austrian national now living in Switzerland. He previously led the company’s Near East region from Turkey, and took over international operations in 2015.
Doustdar told reporters Tuesday that even though he hasn’t led U.S. operations, he thinks he is the right person for the job. He said that being part of the executive leadership team for the past 10 years has helped him learn about the U.S. business. Novo Nordisk generates more than half of its global sales from the U.S.
Novo Nordisk Chairman Helge Lund said Doustdar was a unanimous choice by the board to succeed Jorgensen. “It was also important to us that he’s a challenger,” Lund said. “He goes for clarity and action. He knows the strengths and the weaknesses so he can respond and take action.”
Hanne Sindbæk, a Danish author who has written two books about Novo Nordisk, said Doustdar is more commercially oriented than his predecessor, Jorgensen.
“I think that’s what they want because Eli Lilly has taken the lead in the U.S. now and that’s not OK for a company who defined that market with Ozempic,” Sindbæk said. “They shouldn’t have been overtaken like that.”
Advertisement
She expects Doustdar to make cuts to the workforce because it has grown so much in recent years. Doustdar hinted at that on Tuesday, saying he planned to realign the cost base.
Still, Jefferies analyst Benjamin Jackson said he was surprised that Novo Nordisk promoted an insider, rather than bring in an external candidate as leader, given the company’s recent issues.
The company’s search considered both internal and external candidates for the top job, Lund said.
Novo Nordisk needs to be more aggressive in trying to curtail the compounded semaglutide business in the U.S., by taking more legal actions, analysts say. Novo Nordisk said it has filed numerous lawsuits and sent many cease-and-desist letters to sellers of compounded semaglutide.
Novo Nordisk is trying to bounce back from the Hims & Hers breakdown by seeking other partnerships. The company recently expanded a partnership with WW International to provide increased access to brand-name Wegovy through Weight Watchers clinics.
Analysts also say Novo Nordisk needs to improve its research pipeline of potential new anti-obesity drugs, if it wants to stay competitive with Lilly and other companies seeking to enter the booming market.
Write to Peter Loftus at Peter.Loftus@wsj.com
4 Likes
Den er ikke postet nei. Men er bak betalingsmur. Kan du gi et bittelite overblikk over artikkelen? Hvor lang tid brukte deltakerne på å legge på seg igjen?
For nyere høydose-medisiner som Wegovy og Mounjaro, er effekten enda tydeligere.
Pasienter som bruker disse medisinene går i gjennomsnitt ned 16 kilo, men legger på seg 9,6 kilo i løpet av det første året etter at de slutter.
Med denne hastigheten vil de sannsynligvis ha lagt på seg alle de 16 kiloene igjen i løpet av litt over 20 måneder, ifølge studien.
–
Et av de største problemene
– Det er faktisk en større utfordring at folk slutter med medisinen allerede etter kort tid. Etter ett år har omtrent halvparten sluttet, sier Jøran Hjelmesæth, professor ved Universitetet i Oslo og seksjonsoverlege ved Sykehuset i Vestfold.
Han mener dette er et av de største problemene – at pasienter ikke bruker behandlingen lenge nok til å få varig effekt.
Den nye studien viser at deltakere i snitt gikk ned 16 kilo, men la på seg rundt 10 kilo igjen etter ett år uten medisin. Hjelmesæth understreker likevel at det er forskjell på gamle og nye medikamenter.
– Jeg ville fokusert på de nye, nemlig Wegovy og Mounjaro. Der ser vi at mange faktisk klarer å opprettholde vekten etter et år – mellom en tredjedel og halvparten, sier han.
4 Likes
Takk 
Altså, at folk som i utgangspunktet har vært overvektige legger på seg igjen når de slutter med slankemedisiner og ikke har gjort drastiske livsstilsforandringer (mosjon/ernæring) er vel ikke veldig overraskende? Har skrevet litt om det i fedmebehandling som investeringsmulighet-tråden, at det trolig kommer til å bli et marked for vedlikeholdsterapier etter oppnått ønsket vekttap. Var en artikkel i D2 her i vinter (?) om folk som mikrodoserte Wegovy (mindre doser enn NVO anbefaler / har godkjent) for å vedlikeholde vekttapet de har oppnådd.
På sikt tipper jeg lavdose piller (f.eks ikke-peptid small molecules som orforglipron) eller amylinanaloger (Cagrilintide f.eks) vil kunne være vedlikeholdsterapier. Førstnevnte vil være billig. Og det betyr jo noe om man skal stå på det et tosifret antall år. Sistnevnte vil kanskje ha mindre bivirkninger, og det betyr jo også noe. Mange er nok villige til ubehag i en periode for å få vektnedgang, men ønsker ikke å oppleve det samme ubehaget kronisk.
Og så tipper jeg at det vil bli et (større) marked for ernæringsfysiologer / coaching. Har man først gått gjennom en masse ubehag for å miste vekt + betalt i dyre dommer for det, så tenker man vel også at man kan bruke litt penger på å få hjelp til å utføre de nødvendige livsstilsendringene? Kanskje vil det være et marked for en “Slankeadams matkasse”-variant elns?
@Savepig noen tanker om det absurde volumet?
4 Likes
Vanligvis pleier vi jo å kunne se noen endringer på topp50 når vi ser den type crazyvolum men vet ikke om sånt er tilgjengelig i Danmark?
Det der ser jo ut som om typ Blackrock kastet kortene eller noe
Edit: Kaster meg på og prøver en trade her på 318
1 Like
Vært to ganger nedom 316 nå, kanskje det er et nivå hvor markedet er sultne?
Aksjen er nede på 2022-nivåer hvor den sist gikk fra 350 til 1100.
Slike mega-caps har en evne til å recovre seg, blant annet med reisen til Nvidia som knakk fra 145 til 103 og nå på ny ATH 177, alt innenfor seks måneder 
«Alle» trodde der var game over fordi Deep Seek dukket opp av intet. Når realitetene synker inn og man skjønner at Novo fortsatt er en pengemaskin i et potent marked tror jeg reprisingen kommer.
3 Likes
Jeg handler kun på chart og tredagersregel her, så har voldsomt lave forventninger til denne traden.
Aner ingenting om prisingmultipler eller fundamentale trekk ved selskapet
2 Likes
Frister veldig å øke min eksponering i denne, men det føles jo litt som «when in trouble, then double» og det funker jo bare sånn passe.
Jeg gjorde det nylig i Autostore, lastet innpå på 5 og vippet ut igjen etter 40 % rekyl.
Var ikke mye tillit til aksjen da heller, men det fine med store aksjer er at de dukker opp på radaren til ulike miljøer bare de får juling nok.
Trygg og confident blir man jo aldri, men at Novo kan hente seg godt igjen tror jeg sterkt på. Handle når det gjør vondt er ikke alltid feil 
3 Likes
Kjøp etter 7 august er mitt tips, da har både novo og eli levert resultater
mulig man går glipp av noen få % på det, men risk-offen vil være mye bedre
4 Likes
Den har vel strengt tatt blitt repriset pga endret guiding + div.
Konkurrentene er jo mangfold, så eksempelet med deep seek og nvidia er jo ikke heelt sammenlignbart. Skjønner dog hvor du vil hen.
Har sett på denne en stund. Er viden kjent at turen til 1100 var drevet av fedme, og spacet har fylt seg, gjerne naturlig at den faller med siste tids nyheter som tillegg.
1 Like
AI er perfekt for å kverne kvartalsrapporter og regne multipler.
Er virkelig ikke avskrekkende prising på aksjen akkurat nå, om man ikke lærer nye negative ting på kvartalsrapporten da
5 Likes
Hvis managementet og styre har klart å holde igjen enda en runde med negativt ladet budskap til 6.august, etter alt som har kommet siste månedene med 2 x nedjusteringer og kick out av CEO, tror jeg de skriver historie i bad governance blant mega-caps, men klart det KAN skje.
Hybrid; de har gått fra å være priset som et svulstig vekstselskap med høye forventninger frem i tid til et «undervurdert» verdiselskap.
2 Likes
Nå poster trumpern om novo nordisk på truth social, forklarer muligens duppen i us for øyeblikket
1 Like
2 Likes
hjelpes, nå er han på krigsstien 
Hjelper kompisene sine inn i billige Pharma-aksjer før han chickens out igjen? 
2 Likes